Home Events PD-L1 CPS Testing In Upper GI: Implementation And Scoring – Co-Developed with Bristol Myers Squibb

PD-L1 CPS Testing In Upper GI: Implementation And Scoring – Co-Developed with Bristol Myers Squibb

Date

November 03 2021

Time

1:00 pm - 2:30 pm

Speakers

  • Dr. Brandon Sheffield
    Dr. Brandon Sheffield

    Dr. Sheffield is an anatomic and molecular pathologist. He is currently serving as the Medical Director of Immunohistochemistry and Molecular Pathology and the Physician Lead of Research for the William Osler Health System in Canada. Dr. Sheffield focuses on the delivery of personalized medicine and precision oncology and making molecular testing available to community cancer patients in Canada.

  • Dr. P Fiset

    Pierre-Olivier Fiset MDCM, PhD, FRCPC is an Anatomical Pathologist practicing at the McGill University Health Centre Glen site since 2016. He completed his PhD under the supervision of Dr Qutayba Hamid at the Meakins-Christie Institute. He is a medical graduate from McGill University (2010) and completed his residency in Anatomical Pathology (2015) also at McGill University. He completed his fellowship in Thoracic Pathology (2016) in the University of Toronto Laboratory Medicine and Pathobiology program under the supervision of Dr David Hwang and Dr Ming-Sound Tsao. His practice consists of Thoracic Pathology, Gastrointestinal Pathology, Medical Renal Pathology and Biomarker and Molecular Pathology. He participates in numerous research endeavors and has acted as an expert consultant in each of these respective fields.

OBJECTIVES:

  • Appreciate recent clinical trials data of immunotherapy trial for gastroesophageal cancers
  • TPS and CPS scoring systems, Apply PD-L1 score reports
  • Recognize limitations of tissue for expanding needs of biomarker testing

Description: Recent clinical trials show a benefit for immunotherapy in upper gastrointestinal (esophagus, gastroesophageal junction and stomach) adenocarcinoma. The presentation will describe testing for PD-L1 using the Combined Positive Score (CPS). The discussion will include experience in implementation of the 28-8 PharmDx in an academic institution. Dynacare based options will also be discussed.

Co-Developed with: